Avastin Benefits Not Affected by KRAS Mutations

Colorectal cancer patients with a KRAS mutation in their tumors benefit when Avastin® (bevacizumab) is added to chemotherapy, as do patients with no mutation or wild-type KRAS. Both the time until cancer got worse (progression-free survival) and time patients lived after beginning treatment (survival) were better when Avastin was added to chemotherapy regardless of tumor KRAS…  Read More